Long-term outcome of young onset Parkinson's disease after subthalamic stimulation--a cross-sectional study

Clin Neurol Neurosurg. 2013 Oct;115(10):2082-7. doi: 10.1016/j.clineuro.2013.07.014. Epub 2013 Aug 3.

Abstract

Objective: Age of onset is considered a poor prognostic factor for subthalamic deep brain stimulation (STN-DBS) outcome in the case of Parkinson's disease (PD). The goal of current study is to identify the long-term impact of STN-DBS for young onset PD (YOPD) patients.

Methods: 17 YOPD patients with a mean disease onset at 32.3 years were prospectively followed up at 1, 2, 5 and 7 years after STN-DBS. Unified Parkinson's disease rating scale (UPDRS) was evaluated in 4 combinations of Med/DBS on/off.

Results: UPDRS part II-IV improved significantly 7 years after operation. While a slowly progressive worsening of levodopa response on part III, synergistic effect of medication and stimulation consistently improves motor disabilities. STN-DBS could remarkably reduce levodopa equivalent daily dose at 7 years. The morbidity rates were low. However, these patients seem to have more transient stimulation dyskinesia (47.1%) and dopamine dysregulation syndrome (11.8%) after surgery.

Conclusions: STN-DBS remains effective to improve motor disabilities over 7 years for YOPD and is a safe procedure concerning cognitive outcome and morbidity. However, stimulation dyskinesia and dopamine dysregulation syndrome deserve attention for the causal relationship between DBS surgery and behavioral outcomes.

Keywords: Deep brain stimulation; Subthalamic nucleus; Young onset Parkinson's disease.

MeSH terms

  • Activities of Daily Living
  • Adult
  • Age of Onset
  • Antiparkinson Agents / therapeutic use
  • Cognition / physiology
  • Cohort Studies
  • Cross-Sectional Studies
  • Deep Brain Stimulation / methods*
  • Female
  • Follow-Up Studies
  • Humans
  • Levodopa / therapeutic use
  • Male
  • Mental Disorders / epidemiology
  • Mental Disorders / etiology
  • Mental Disorders / therapy
  • Middle Aged
  • Movement Disorders / epidemiology
  • Movement Disorders / etiology
  • Movement Disorders / therapy
  • Parkinson Disease / drug therapy
  • Parkinson Disease / therapy*
  • Prognosis
  • Subthalamic Nucleus / physiology*
  • Treatment Outcome

Substances

  • Antiparkinson Agents
  • Levodopa